Prodromos Sidiropoulos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Prodromos Sidiropoulos has a total of 274 co-authors. Here are the top co-authors by number of shared publications:
- George Bertsias
Rheumatology, Clinical Immunology, Medical School, University of Crete, Heraklion, Greece
23 shared publications - Dimitrios T. Boumpas
Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece
13 shared publications - Irini Flouri
Rheumatology, Clinical Immunology, Medical School, University of Crete, Heraklion, Greece
11 shared publications - Antonis Fanouriakis
Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece
10 shared publications - Argyro Repa
Rheumatology, Clinical Immunology, Medical School, University of Crete, Heraklion, Greece
10 shared publications Argyro Repa
Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece
9 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Springer Nature in Arthritis Research & Therapy
Obesity and fibromyalgia are associated with a difficult-to-manage psoriatic arthritis phenotype and adverse long-term outcomes
- 12 November 2026
- Published by Springer Nature in Arthritis Research & Therapy
Open AccessObesity and fibromyalgia are associated with a difficult-to-manage psoriatic arthritis phenotype and adverse long-term outcomes
- Open Access
- 5 October 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (10) , 276
Baricitinib retention and factors associated thereof in clinical practice: a prospective, multicenter 12-month study in rheumatoid arthritis patients
Herein we report for baricitinib drug retention, predictors thereof and clinical responses in rheumatoid arthritis (RA) patients with a special focus in comorbidities. Prospective, multicenter, observational study of RA patients starting baricitinib because of active disease. Patients were followed every 3 months for 12 months. The primary endpoint was baricitinib retention at 12 months; predictors for survival and clinical responses at 6 months were secondary endpoints. Retention rate was estimated by Kaplan–Meier (K-M) while predictors of discontinuation by Cox regression. We recruited 135 patients, 93.3% females, mean (standard deviation-SD) age 56.1 (10.1) years, median (interquartile range) disease duration 57 (90) months. 18.5% started baricitinib as first line targeted therapy. 35.9% (28/88) and 44.1% (26/59) achieved DAS28 remission/low disease activity (LDA) at 6 and 12 months respectively. Baricitinib retention at 12 months was 68.9%. K-M analysis showed that hypertension (p=0.049), latent tuberculosis infection (LTBi) (p=0.007) and depression (p=0.005) were associated to lower retention, while multivariate analysis showed that depression [Hazard ratio (HR) 2.715, p=0.007] and LTBi (HR 2.519, p=0.020) predicted baricitinib discontinuation. Analysis for patients on therapy for at least 6 months showed that together with hypertension (HR 2.477, p=0.022) and LTBi (HR 3.761, p=0.023), higher DAS28 at 6 months (HR 1.434, p=0.024) predicted baricitinib discontinuation at 12 months. In established RA, 68.9% of the patients remained on baricitinib at 12 months and had an improvement of disease activity. Mostly comorbidities contributed to baricitinib persistence, supporting their importance as factors to be addressed to optimize RA clinical care.
- 5 October 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (10) , 276
Open AccessBaricitinib retention and factors associated thereof in clinical practice: a prospective, multicenter 12-month study in rheumatoid arthritis patients
Herein we report for baricitinib drug retention, predictors thereof and clinical responses in rheumatoid arthritis (RA) patients with a special focus in comorbidities. Prospective, multicenter, observational study of RA patients starting baricitinib because of active disease. Patients were followed every 3 months for 12 months. The primary endpoint was baricitinib retention at 12 months; predictors for survival and clinical responses at 6 months were secondary endpoints. Retention rate was estimated by Kaplan–Meier (K-M) while predictors of discontinuation by Cox regression. We recruited 135 patients, 93.3% females, mean (standard deviation-SD) age 56.1 (10.1) years, median (interquartile range) disease duration 57 (90) months. 18.5% started baricitinib as first line targeted therapy. 35.9% (28/88) and 44.1% (26/59) achieved DAS28 remission/low disease activity (LDA) at 6 and 12 months respectively. Baricitinib retention at 12 months was 68.9%. K-M analysis showed that hypertension (p=0.049), latent tuberculosis infection (LTBi) (p=0.007) and depression (p=0.005) were associated to lower retention, while multivariate analysis showed that depression [Hazard ratio (HR) 2.715, p=0.007] and LTBi (HR 2.519, p=0.020) predicted baricitinib discontinuation. Analysis for patients on therapy for at least 6 months showed that together with hypertension (HR 2.477, p=0.022) and LTBi (HR 3.761, p=0.023), higher DAS28 at 6 months (HR 1.434, p=0.024) predicted baricitinib discontinuation at 12 months. In established RA, 68.9% of the patients remained on baricitinib at 12 months and had an improvement of disease activity. Mostly comorbidities contributed to baricitinib persistence, supporting their importance as factors to be addressed to optimize RA clinical care.
- Open Access
Early SLE may follow a fast comorbidity/multimorbidity trajectory associated with flare burden and glucocorticoid exposure
Background: Patients with systemic lupus erythematosus (SLE) carry a substantial comorbidity load associated with worse prognosis, yet most evidence pertains to long-standing disease. How comorbidities—particularly multimorbidity as a marker of overall health burden—evolve at early stages, and whether conditions co-aggregate into clinically meaningful clusters, remains unclear. Methods: An inception cohort (≤2 years from diagnosis) of 311 patients with SLE with 5-year monitoring of 140 comorbidities, disease activity, treatments, organ damage and adverse events/hospitalisations. Growth mixture modelling identified trajectories of incident comorbidities, while tetrachoric exploratory factor analysis followed by clustering defined multimorbidity profiles; these trajectories and profiles were then related to longitudinal outcomes. To inform temporal ordering, trajectory modelling was refitted for months 24–60, and predictors from <24 months were evaluated using penalised multivariable regression. Results: Early SLE separated into slow (55%) and fast (45%) incident-comorbidity trajectories. Among fast accruers, three phenotypes emerged: low-to-moderate (general/non-patterned) (51%), metabolic-psychiatric (31%) and cardiopulmonary-musculoskeletal (18%), with a gradual increase in multimorbidity (≥2 conditions) (32.7%, 65.7% and 100%, respectively). Compared with slow-accruing, fast-accruing patients—especially the metabolic-psychiatric and cardiopulmonary-musculoskeletal—attained less lupus low disease activity state/Definition of Remission In SLE and developed more damage (incidence rate ratio (IRR) 2.28–3.27) and safety-related events (IRR 1.89–3.36). Severe flares (≥20% of time; OR 2.10, 95% CI 1.09 to 4.04) and glucocorticoid exposure (OR 1.06 per 10 mg/day, 95% CI 1.01 to 1.11) during the first 24 months independently predicted subsequent fast-comorbidity trajectory. Flares were more prominent in the fast/low-to-moderate and metabolic-psychiatric phenotypes, whereas glucocorticoid use was more prominent in the cardiopulmonary-musculoskeletal phenotype. Conclusions: Nearly half of patients with newly diagnosed SLE show accelerated comorbidity and multimorbidity burden, underscoring the need for clinical vigilance. Fast-accrual phenotypes are linked to flares and glucocorticoid exposure, two potentially modifiable features of early disease.
Open AccessEarly SLE may follow a fast comorbidity/multimorbidity trajectory associated with flare burden and glucocorticoid exposure
Background: Patients with systemic lupus erythematosus (SLE) carry a substantial comorbidity load associated with worse prognosis, yet most evidence pertains to long-standing disease. How comorbidities—particularly multimorbidity as a marker of overall health burden—evolve at early stages, and whether conditions co-aggregate into clinically meaningful clusters, remains unclear. Methods: An inception cohort (≤2 years from diagnosis) of 311 patients with SLE with 5-year monitoring of 140 comorbidities, disease activity, treatments, organ damage and adverse events/hospitalisations. Growth mixture modelling identified trajectories of incident comorbidities, while tetrachoric exploratory factor analysis followed by clustering defined multimorbidity profiles; these trajectories and profiles were then related to longitudinal outcomes. To inform temporal ordering, trajectory modelling was refitted for months 24–60, and predictors from <24 months were evaluated using penalised multivariable regression. Results: Early SLE separated into slow (55%) and fast (45%) incident-comorbidity trajectories. Among fast accruers, three phenotypes emerged: low-to-moderate (general/non-patterned) (51%), metabolic-psychiatric (31%) and cardiopulmonary-musculoskeletal (18%), with a gradual increase in multimorbidity (≥2 conditions) (32.7%, 65.7% and 100%, respectively). Compared with slow-accruing, fast-accruing patients—especially the metabolic-psychiatric and cardiopulmonary-musculoskeletal—attained less lupus low disease activity state/Definition of Remission In SLE and developed more damage (incidence rate ratio (IRR) 2.28–3.27) and safety-related events (IRR 1.89–3.36). Severe flares (≥20% of time; OR 2.10, 95% CI 1.09 to 4.04) and glucocorticoid exposure (OR 1.06 per 10 mg/day, 95% CI 1.01 to 1.11) during the first 24 months independently predicted subsequent fast-comorbidity trajectory. Flares were more prominent in the fast/low-to-moderate and metabolic-psychiatric phenotypes, whereas glucocorticoid use was more prominent in the cardiopulmonary-musculoskeletal phenotype. Conclusions: Nearly half of patients with newly diagnosed SLE show accelerated comorbidity and multimorbidity burden, underscoring the need for clinical vigilance. Fast-accrual phenotypes are linked to flares and glucocorticoid exposure, two potentially modifiable features of early disease.
- Open Access
- 24 January 2026
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 28 (1)
Difficult to manage axial spondyloarthritis patients have high burden of pain-related comorbidities and adverse long-term outcome
Difficult to manage (D2M) axial spondyloarthritis (axSpA) is an evolving clinical concept. We aimed to assess the prevalence, predictors and long-term outc
- 24 January 2026
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 28 (1)
Open AccessDifficult to manage axial spondyloarthritis patients have high burden of pain-related comorbidities and adverse long-term outcome
Difficult to manage (D2M) axial spondyloarthritis (axSpA) is an evolving clinical concept. We aimed to assess the prevalence, predictors and long-term outc
- Open Access
Distinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data from a multicentre cohort study
Background: Remission and low-disease activity are recommended targets in systemic lupus erythematosus (SLE), yet many patients fail to achieve them, underscoring the need to identify contributing barriers. We explored whether comorbidities—some of which share genetic risk with lupus—and their specific patterns influence target accomplishment. Methods: Retrospective cohort of 347 patients with active SLE receiving treatment intensification at inclusion. Comorbidities (n=140), disease activity, treatments and organ damage were monitored (median follow-up 5 years). Mixed-effects assessed relationships between comorbidities and definitions of remission in SLE/lupus low disease activity state (DORIS/LLDAS). Random forests ranked comorbidities according to the strength of associations. Results: Despite the relatively young age (median 46 years) and short disease duration (median 9 months), patients with SLE exhibited high comorbidity burden (comorbidities count, Rheumatic Disease Comorbidity Index, Elixhauser, Charlson), which increased longitudinally and was associated with reduced attainment of DORIS (ORs: 0.77–0.87, p<0.05) and LLDAS (ORs: 0.74–0.91, p<0.01). Obesity, dyslipidaemia, hypertension, stroke, depression, fibromyalgia and thyroid disorders emerged as the most influential. Presence of ≥1 of these conditions (n=238 [68.6%]) was linked to 55–60% lower likelihood of durable DORIS/LLDAS (≥50% time). Marginal structural models (MSMs) confirmed an independent comorbidities-targets association, regardless of prior achievement, explained by smouldering activity and delayed glucocorticoid tapering. While immunosuppressant/biologic use was comparable, comorbid patients received lower glucocorticoid doses during high disease activity. Comorbidities were also associated with greater damage accrual (IRR: 1.38, 95% CI 1.11 to 1.71), attenuated in patients with sustained DORIS/LLDAS. Conclusions: Patients with SLE manifest high comorbidity burden, with distinct patterns linked to reduced target attainment. In these patients, vigilant monitoring and treatment adjustments are essential to sustain disease control and prevent damage.
Open AccessDistinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data from a multicentre cohort study
Background: Remission and low-disease activity are recommended targets in systemic lupus erythematosus (SLE), yet many patients fail to achieve them, underscoring the need to identify contributing barriers. We explored whether comorbidities—some of which share genetic risk with lupus—and their specific patterns influence target accomplishment. Methods: Retrospective cohort of 347 patients with active SLE receiving treatment intensification at inclusion. Comorbidities (n=140), disease activity, treatments and organ damage were monitored (median follow-up 5 years). Mixed-effects assessed relationships between comorbidities and definitions of remission in SLE/lupus low disease activity state (DORIS/LLDAS). Random forests ranked comorbidities according to the strength of associations. Results: Despite the relatively young age (median 46 years) and short disease duration (median 9 months), patients with SLE exhibited high comorbidity burden (comorbidities count, Rheumatic Disease Comorbidity Index, Elixhauser, Charlson), which increased longitudinally and was associated with reduced attainment of DORIS (ORs: 0.77–0.87, p<0.05) and LLDAS (ORs: 0.74–0.91, p<0.01). Obesity, dyslipidaemia, hypertension, stroke, depression, fibromyalgia and thyroid disorders emerged as the most influential. Presence of ≥1 of these conditions (n=238 [68.6%]) was linked to 55–60% lower likelihood of durable DORIS/LLDAS (≥50% time). Marginal structural models (MSMs) confirmed an independent comorbidities-targets association, regardless of prior achievement, explained by smouldering activity and delayed glucocorticoid tapering. While immunosuppressant/biologic use was comparable, comorbid patients received lower glucocorticoid doses during high disease activity. Comorbidities were also associated with greater damage accrual (IRR: 1.38, 95% CI 1.11 to 1.71), attenuated in patients with sustained DORIS/LLDAS. Conclusions: Patients with SLE manifest high comorbidity burden, with distinct patterns linked to reduced target attainment. In these patients, vigilant monitoring and treatment adjustments are essential to sustain disease control and prevent damage.
- Open Access
- 3 November 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 1-14
Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex
The anti-interleukin 17A agent secukinumab has been approved for the treatment of spondyloarthritis (SpA) patients as an alternative to tumor necrosis factor inhibitors (TNFis). Our aim was to compare long-term treatment persistence and relevant effect modifiers, as well as 6-month clinical responses, in SpA patients starting secukinumab versus TNFis in routine clinical care. This was a prospective single-center cohort study of consecutive axial SpA (axSpA) or peripheral SpA (perSpA) patients, including psoriatic arthritis (PsA) patients, who started or switched to either secukinumab or TNFis from 2016–2022. Drug persistence and low/minimal disease activity rates were assessed via Kaplan‒Meier curves and multivariable and propensity score-adjusted regression analyses. Confounding and effect modification were tested for several baseline demographic, clinical and laboratory characteristics. A total of 644 patients (secukinumab: 214, TNFis: 430) were analyzed. Unadjusted 4-year treatment persistence was greater with secukinumab than with TNFis in the total SpA cohort (38.7% versus 30.5%, respectively, log-rank p = 0.004); including the axSpA (37% versus 34.5%, p = 0.044) and perSpA (40% versus 18.2%, p = 0.011) cohorts. Multivariable analysis confirmed a greater risk for discontinuation of TNFis [HR (95% CI): 1.62 (1.23–2.14), p < 0.001] both for inefficacy [1.38 (1.01–1.90)] and safety reasons [2.95 (1.22–7.14)]. Psoriatic arthritis, obesity and female sex significantly modified the differential efficacy-related persistence. The 2-year persistence in obese female psoriatic arthritis patients was 76% with secukinumab versus 39% with TNFis, whereas in nonobese axSpA males, it was 48% versus 78%, respectively. Six-month treatment target achievement rates were comparable between the two agents in axSpA, perSpA, and PsA patients. The differential persistence of biologic agents commonly used in SpA has been shown in this real-life prospective study. Should the distinct effects of obesity, sex and specific SpA diagnosis on persistence be confirmed in other cohorts, it could optimize clinical decision-making and improve patient outcomes.
- 3 November 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 1-14
Open AccessLong-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex
The anti-interleukin 17A agent secukinumab has been approved for the treatment of spondyloarthritis (SpA) patients as an alternative to tumor necrosis factor inhibitors (TNFis). Our aim was to compare long-term treatment persistence and relevant effect modifiers, as well as 6-month clinical responses, in SpA patients starting secukinumab versus TNFis in routine clinical care. This was a prospective single-center cohort study of consecutive axial SpA (axSpA) or peripheral SpA (perSpA) patients, including psoriatic arthritis (PsA) patients, who started or switched to either secukinumab or TNFis from 2016–2022. Drug persistence and low/minimal disease activity rates were assessed via Kaplan‒Meier curves and multivariable and propensity score-adjusted regression analyses. Confounding and effect modification were tested for several baseline demographic, clinical and laboratory characteristics. A total of 644 patients (secukinumab: 214, TNFis: 430) were analyzed. Unadjusted 4-year treatment persistence was greater with secukinumab than with TNFis in the total SpA cohort (38.7% versus 30.5%, respectively, log-rank p = 0.004); including the axSpA (37% versus 34.5%, p = 0.044) and perSpA (40% versus 18.2%, p = 0.011) cohorts. Multivariable analysis confirmed a greater risk for discontinuation of TNFis [HR (95% CI): 1.62 (1.23–2.14), p < 0.001] both for inefficacy [1.38 (1.01–1.90)] and safety reasons [2.95 (1.22–7.14)]. Psoriatic arthritis, obesity and female sex significantly modified the differential efficacy-related persistence. The 2-year persistence in obese female psoriatic arthritis patients was 76% with secukinumab versus 39% with TNFis, whereas in nonobese axSpA males, it was 48% versus 78%, respectively. Six-month treatment target achievement rates were comparable between the two agents in axSpA, perSpA, and PsA patients. The differential persistence of biologic agents commonly used in SpA has been shown in this real-life prospective study. Should the distinct effects of obesity, sex and specific SpA diagnosis on persistence be confirmed in other cohorts, it could optimize clinical decision-making and improve patient outcomes.
- Open Access
- 30 October 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Comparable 12-month renal response outcomes with medium- vs high-dose starting prednisone in a real-world study of Lupus Nephritis
Objective: The optimal starting dose and tapering of glucocorticoids (GC) in LN remains unknown. We aimed to assess whether a higher prednisone dose results in better 12-month complete renal response (CRR) rates compared with a lower dose, in a contemporary multicentre cohort of LN patients. Methods: Retrospective and prospective cohort study of patients with new-onset biopsy-proven LN (period 2014–to date). Overall and complete renal response rates at 12 months were compared between patients who started with high (>40 mg/day) vs low-medium (≤40 mg/day) prednisone dose. Multivariable regression and time-to-response analyses were performed, applying inverse probability of treatment weighting (IPTW) to balance baseline covariates and minimize confounding. Results: A total of 162 patients were included; 101 received a low-medium starting prednisone dose (median 30 mg/day) and 61 received a high dose (median 60 mg/day). Cumulative prednisone exposure in the first year was significantly higher in the high-dose group (6.9 g vs 4.0 g; P < 0.001), although cumulative doses equalized by years 2 and 3. The 12-month CRR rates were comparable between the high- and medium-dose groups (65.4% in the low-medium vs 71.2% in the high-dose group, P = 0.55). In multivariable logistic regression with IPTW, a higher initial prednisone dose was not associated with better CRR rate (adjusted OR 1.00; 95% CI: 0.46–2.22). Similarly, time-to-response analyses showed no difference in achieving overall renal response (log-rank P = 0.26). Conclusion: Despite significantly increasing GC exposure, a higher starting prednisone dose was not associated with improved renal response rates at 12 months in a contemporary LN cohort.
- 30 October 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Open AccessComparable 12-month renal response outcomes with medium- vs high-dose starting prednisone in a real-world study of Lupus Nephritis
Objective: The optimal starting dose and tapering of glucocorticoids (GC) in LN remains unknown. We aimed to assess whether a higher prednisone dose results in better 12-month complete renal response (CRR) rates compared with a lower dose, in a contemporary multicentre cohort of LN patients. Methods: Retrospective and prospective cohort study of patients with new-onset biopsy-proven LN (period 2014–to date). Overall and complete renal response rates at 12 months were compared between patients who started with high (>40 mg/day) vs low-medium (≤40 mg/day) prednisone dose. Multivariable regression and time-to-response analyses were performed, applying inverse probability of treatment weighting (IPTW) to balance baseline covariates and minimize confounding. Results: A total of 162 patients were included; 101 received a low-medium starting prednisone dose (median 30 mg/day) and 61 received a high dose (median 60 mg/day). Cumulative prednisone exposure in the first year was significantly higher in the high-dose group (6.9 g vs 4.0 g; P < 0.001), although cumulative doses equalized by years 2 and 3. The 12-month CRR rates were comparable between the high- and medium-dose groups (65.4% in the low-medium vs 71.2% in the high-dose group, P = 0.55). In multivariable logistic regression with IPTW, a higher initial prednisone dose was not associated with better CRR rate (adjusted OR 1.00; 95% CI: 0.46–2.22). Similarly, time-to-response analyses showed no difference in achieving overall renal response (log-rank P = 0.26). Conclusion: Despite significantly increasing GC exposure, a higher starting prednisone dose was not associated with improved renal response rates at 12 months in a contemporary LN cohort.
- Open Access
Systemic lupus erythematosus damage risk index (SLE-DRI): a simple machine learning-based tool for identifying patients at risk for early organ damage
Objective: Organ damage is a key determinant of poor prognosis and increased mortality in systemic lupus erythematosus (SLE). However, no validated clinical tools for predicting damage accumulation currently exist. We sought to develop a machine learning-based model to predict early organ damage in patients with SLE. Methods: Classification criteria (American College of Rheumatology (ACR)-1997, Systemic Lupus International Collaborating Clinics (SLICC)-2012, European League Against Rheumatism (EULAR)/ACR-2019) and non-criteria features of a cohort of 914 patients with SLE were analysed to predict damage (defined as SLICC/ACR Damage Index (SDI)) within 5 years since diagnosis. Feature selection and model construction were performed using the least absolute shrinkage and selection operator-logistic regression (LASSO-LR). The best model in 10-fold cross-validation was tested in an external cohort (n=50). Results: A LASSO-LR model incorporating 16 criteria and non-criteria features predicted early organ damage with area under the receiver operating characteristic curve (AUC) values of 0.80 (95% CI 0.74 to 0.87) and 0.86 (95% CI 0.76 to 0.97) in the derivation and external validation cohorts, respectively, outperforming the ACR-1997 (AUC 0.70; 95% CI 0.62 to 0.78), SLICC-2012 (AUC 0.74; 95% CI 0.66 to 0.81) and EULAR/ACR-2019 (AUC 0.70; 95% CI 0.63 to 0.78) classification systems. Features most strongly associated with damage included the SLICC-2012 neurological disorder, EULAR/ACR-2019 class III/IV lupus nephritis and among non-criteria manifestations, myocarditis and interstitial lung disease. Operating the model as a binary classifier (early damage versus no damage), it demonstrated high specificity (0.90, 95% CI 0.78 to 0.95). The model can be converted to a simplified scoring system, with a threshold of ≥3 achieving an AUC of 0.86 (95% CI 0.75 to 0.96). Conclusion: We developed and validated a clinician-friendly model for early organ damage prediction in SLE, facilitating risk stratification.
Open AccessSystemic lupus erythematosus damage risk index (SLE-DRI): a simple machine learning-based tool for identifying patients at risk for early organ damage
Objective: Organ damage is a key determinant of poor prognosis and increased mortality in systemic lupus erythematosus (SLE). However, no validated clinical tools for predicting damage accumulation currently exist. We sought to develop a machine learning-based model to predict early organ damage in patients with SLE. Methods: Classification criteria (American College of Rheumatology (ACR)-1997, Systemic Lupus International Collaborating Clinics (SLICC)-2012, European League Against Rheumatism (EULAR)/ACR-2019) and non-criteria features of a cohort of 914 patients with SLE were analysed to predict damage (defined as SLICC/ACR Damage Index (SDI)) within 5 years since diagnosis. Feature selection and model construction were performed using the least absolute shrinkage and selection operator-logistic regression (LASSO-LR). The best model in 10-fold cross-validation was tested in an external cohort (n=50). Results: A LASSO-LR model incorporating 16 criteria and non-criteria features predicted early organ damage with area under the receiver operating characteristic curve (AUC) values of 0.80 (95% CI 0.74 to 0.87) and 0.86 (95% CI 0.76 to 0.97) in the derivation and external validation cohorts, respectively, outperforming the ACR-1997 (AUC 0.70; 95% CI 0.62 to 0.78), SLICC-2012 (AUC 0.74; 95% CI 0.66 to 0.81) and EULAR/ACR-2019 (AUC 0.70; 95% CI 0.63 to 0.78) classification systems. Features most strongly associated with damage included the SLICC-2012 neurological disorder, EULAR/ACR-2019 class III/IV lupus nephritis and among non-criteria manifestations, myocarditis and interstitial lung disease. Operating the model as a binary classifier (early damage versus no damage), it demonstrated high specificity (0.90, 95% CI 0.78 to 0.95). The model can be converted to a simplified scoring system, with a threshold of ≥3 achieving an AUC of 0.86 (95% CI 0.75 to 0.96). Conclusion: We developed and validated a clinician-friendly model for early organ damage prediction in SLE, facilitating risk stratification.
- Open Access
- 21 January 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1376925
Fibroblasts in rheumatoid arthritis: novel roles in joint inflammation and beyond
High-throughput technologies in human and animal studies have revealed novel molecular and cellular pathways involved in tissue inflammation of rheumatoid arthritis (RA). Fibroblasts have been in the forefront of research for several decades. Subpopulations with specific phenotypic and functional properties have been characterized both in mouse models and human disease. Data supporting the active involvement of fibroblasts in immune responses and tissue remodeling processes, as well as their central role in promoting clinical relapses and contributing to treatment resistance, have clearly reshaped their role in disease evolution. The lung is an important non-synovial component of RA both from a clinical and an immunopathogenic aspect. Interstitial lung disease (ILD) is a significant contributor to disease burden affecting morbidity and mortality. Although our knowledge of ILD has progressed, significant gaps in both basic and clinical science remain, posing hurdles to efficient diagnosis, prediction of disease course and its effective treatment. The specific role and contribution of fibroblasts to this process has not been clearly defined. The focus of this review is on fibroblasts and their contribution to RA and RA-ILD, presenting data on genetics and immune responses associated with RA-ILD in humans and animal models.
- 21 January 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1376925
Open AccessFibroblasts in rheumatoid arthritis: novel roles in joint inflammation and beyond
High-throughput technologies in human and animal studies have revealed novel molecular and cellular pathways involved in tissue inflammation of rheumatoid arthritis (RA). Fibroblasts have been in the forefront of research for several decades. Subpopulations with specific phenotypic and functional properties have been characterized both in mouse models and human disease. Data supporting the active involvement of fibroblasts in immune responses and tissue remodeling processes, as well as their central role in promoting clinical relapses and contributing to treatment resistance, have clearly reshaped their role in disease evolution. The lung is an important non-synovial component of RA both from a clinical and an immunopathogenic aspect. Interstitial lung disease (ILD) is a significant contributor to disease burden affecting morbidity and mortality. Although our knowledge of ILD has progressed, significant gaps in both basic and clinical science remain, posing hurdles to efficient diagnosis, prediction of disease course and its effective treatment. The specific role and contribution of fibroblasts to this process has not been clearly defined. The focus of this review is on fibroblasts and their contribution to RA and RA-ILD, presenting data on genetics and immune responses associated with RA-ILD in humans and animal models.
- 21 January 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1870 (2) , 159596
Dantrolene is an HDL-associated paraoxonase-1 activator with immunosuppressive and atheroprotective properties
- 21 January 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1870 (2) , 159596
Dantrolene is an HDL-associated paraoxonase-1 activator with immunosuppressive and atheroprotective properties